纳米给药系统脑靶向配体的研究进展

doi:10.3969/j.issn.2095-1396.2017.04.003

摘要/Abstract

摘要： 血脑脊液屏障（blood-cerebrospinal fluid barrier，blood-CSF barrier）的存在成为了脑部疾病给药治疗的阻碍，而靶向制剂可以使药物选择性的集中在病灶区域，增加药物的浓度，降低毒副作用，成为目前关于脑部疾病治疗的热门方向。该文综述了近五年内应用较广泛的几大类脑靶向配体和其递送策略。搭载药物的纳米粒子通过受体介导、载体介导、转胞吞作用等不同的方式进行跨膜转运，将药物递送至脑部，使药物在脑内蓄积成为可能，并具有极大的研究和发展前景。

关键词: 血脑脊液屏障, 纳米粒子给药系统, 靶向药物, 受体介导

Abstract: Blood-cerebrospinal fluid barrier hinders the treatment of brain diseases，while targeted agents can not only selectively concentrate on the foci，but also increases the concentration of drugs and thereby reducing the toxicity and side effects，which popularly directs the treatment of brain diseases nowadays. This paper summarizes several brain target ligands applied broadly and their delivery strategies over the last five years，involving drug-carrying nanoparticles that transported to the brain by means of receptor-mediated，vector-mediated，and trans-cell-swallowing，which makes it possible to accumulate drugs in the brain，and needs to be prospectively researched and developed.

Key words: blood-cerebrospinal fluid barrier, nano-scale drug delivery systems, targeted drug, receptor-mediated

中图分类号:

R964

任婧，张丹参. 纳米给药系统脑靶向配体的研究进展[J]. 神经药理学报, 2017, 7(4): 17-25.

REN Jing，ZHANG Dan-shen. Progress in Research of Brain Targeting Ligand for Nano-scale Drug Delivery Systems[J]. Acta Neuropharmacologica, 2017, 7(4): 17-25.

参考文献

[1] Arijit Bhowmik, Rajni Khan, Mrinal K Ghosh. Blood brain barrier: a challenge for effectual therapy of brain tumors[J]. Biomed Res Int, 2015, (2015):320-941.

[2] Inmaculada Posadas, Silvia Monteagudo, Valentin Cena. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis[J]. Nanomed, 2016, 11(2016):833–849.

[3] D Elias, F Blot, A El Otmany, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy[J]. Cancer, 2001, 92(1):71–76.

[4] William M Pardridge. Drug and gene targeting to the brain via blood–brain barrier receptor-mediated transport systems[J]. Int Congr Ser, 1277(2005):49–62.

[5] David Maussang, Jaap Rip, Joan van Kregten, et al. Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo[J]. Drug Discov Today Technol, 2016, 20:59–69.

[6] N Joan Abbott, Adjanie A K Patabendige, Diana E M Dolman, et al. Structure and function of the blood-brain barrier[J]. Neurobiol Dis, 37(2010):13–25.

[7] Mayur M Patel, Bhoomika M Patel. Crossing the blood-brain barrier: recent advances in drug delivery to the brain[J]. CNS Drugs, 31(2017):109–133.

[8] Renu Singh Dhanikula, Anteneh Argaw, Jean-Francois Bouchard, et al. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability[J]. Mol Pharm, 2008, 5(1):105–116.

[9] Yan Chen, Li-hong Liu. Modern methods for delivery of drugs across the blood-brain barrier[J]. Adv Drug Deliv Rev, 2012, 64(7):640–665.

[10] Tetsuya Terasaki, Akira Tsuji. Drug delivery to the brain utilizing blood-brain barrier transport systems[J]. J Control Release, 1994, 29(1-2):163–169.

[11] Hui-le Gao. Progress and perspectives on targeting nanoparticles for brain drug delivery[J]. Acta Pharm Sin, 2016, 6(4):268–286.

[12] Mikko Gynther, Jarmo Ropponen, Krista Laine, et al. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats[J]. J Med Chem, 2009, 52(10):3348–3353.

[13] Maria Joao Gomes, Barbara Mendes, Susana Martins, et al. Nanoparticle functionalization for brain targeting drug delivery and diagnostic[J]. Handbook of Nanoparticles, 2016:941-959.

[14] Hammarlund-Udenaes, Margareta, de Lange, Elizabeth, Thorne, et al. Drug delivery to the brain–physiological concepts, methodologies and approaches[M]. Springer: New York, 2014: 433–454.

[15] Amit Alexander, Ajazuddin, Ravish J Patel, et al. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives[J]. J. Control.Release, 2016, 241:110–124.

[16] Amit Alexander, Ajazuddin, Junaid Khan, et al. Polyethylene glycol (PEG)-poly (N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications[J]. Eur J Pharm Biopharm, 2014, 88(3):575–585.

[17] Amit Alexander, Ajazuddin, Junaid Khan, et al. Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications[J]. J Control Release, 2013, 172(3):715–729.

[18] S Sahu, S Saraf, C D Kaur, et al. Biocompatible nanoparticles for sustained topical delivery of anticancer phytoconstituent quercetin[J]. Pak J Biol Sci, 2013, 16(13):601–609.

[19] Ajazuddin Ajazuddin, Amit Alexander, Junaid Khan, et al.

Advancement in stimuli triggered in situ gelling delivery for local and systemic

route[J]. Expert Opin Drug Deliv, 2012, 9(12):1573–1592.

[20] Amit Alexander, Shubhangi Dwivedi, Ajazuddin, et al. Tripathi, Approaches for breaking the barriers of drug permeation through transdermal drug delivery[J].J Control Release, 2012, 164(1):26–40.

[21] Amber Vyas, Shailendra Saraf, Swarnlata Saraf. Encapsulation of cyclodextrin complexed simvastatin in chitosan nanocarriers: a novel technique for oral delivery[J]. J Incl Phenom Macrocycl Chem, 2010, 66(3-4):251–259.

[22] K Dashora, Swarnlata Saraf. In vitro studies of tizanidine controlled-release

microcapsular matrices[J]. Pak J Pharm Sci, 2006, 19(3):177–181.

[23] R Gabathuler. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases[J]. Neurobiol Dis, 2010, 37(1):48–57.

[24] Torben Moos, Evan H Morgan. Transferrin and transferrin receptor function in brain barrier systems[J]. Cell Mol Neurobiol, 2000, 20(1):77–95.

[25] J B Fishman, J B Rubin, J V Handrahan, et al. Receptormediated transcytosis of transferrin across the blood-brain barrier[J]. J Neurosci Res, 18(2):299–304.

[26] Chen Zhi-lan, Huang Man, Wang Xia-rong, et al. Transferrin-modified liposome promotes alpha-mangostin to penetrate the bloodbrain barrier[J]. Nanomedicine, 2016, 12(2):421–430.

[27] 赵超越, 张云杰, 姜晓艺, 等. 乳铁蛋白作为靶向功能分子的研究进展[J]. 中国生化药物杂志, 2014, 34(09): 181-184.

[28] Y A Suzuki, V Lopez, B Lonnerdal. Mammalian lactoferrin receptors: structure and function[J]. Cell Mol Life Sci, 2005, 62:2560–2575.

[29] Hu Kai-li, Shi Yan-bin, Jiang Wen-ming, et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation，characterization and efficacy in Parkinson's disease[J]. Int J Pharm，2011，415( 1 /2) : 273-283．

[30] 冯亮. 乳铁蛋白修饰聚合物泡囊对脑胶质瘤的递药特性研究[D]. 上海: 复旦大学药学院，2010．

[31] Jean E Vance, Hideki Hayashi. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system[J]. Biochim Biophys Acta, 2010, 1801(8):806–818.

[32] AG De Boer, P J Gaillard. Drug targeting to the brain[J]. Annu Rev Pharmacol Toxicol, 2007, 47:323–355.

[33] Benedicte Dehouck, Laurence Fenart, Marie-Pierre Dehouck, et al. A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier[J]. J Cell Biol, 1997, 138(4):877–889.

[34] K Michaelis, M M Hoffmann, S Dreis, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain[J]. J Pharmacol Exp Ther, 2006, 317(3):1246–1253.

[35] Reinhard Gabathuler. Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases[J]. Neurobiol Dis, 2010, 37(1):48–57.

[36] Anja Zensi, David Begley, Charles Pontikis, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurons[J]. J Controlled Release, 2009, 137(1):78-86.

[37] 秦晶. RGD介导脑靶向阿魏酸脂质体的研究[D].沈阳: 沈阳药科大学，2007.

[38] Pieter J Gaillard, Chantal C M Appeldoorn, Jaap Rip, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation[J]. J Control Release, 2012, 164(3):364–369.

[39] Huang Feng-yun, Chen Wan-jou, Lee Wan-yu, et al. In vitro and in vivoevaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery[J].Int J Mol Sci, 2013,14:2862-2874.

[40] Cheng Gong, Li Xiang-ning, Xu Ling-ling, et al. Target delivery of a gene into the brain using the RVG29-oligoarginine peptide[J]. Biomaterials, 2012, 33(12): 3456-3463.

[41] 况其方, 冉瑞, 刘亚圆, 等. RVG_(29)修饰脂质体对脑胶质瘤靶向性的初步研究[J].华西药学杂志, 2015, 30(01): 15-17.

[42] 金莹莹, 张家文. Angiopep-2修饰的纳米递药系统和纳米成像系统在胶质瘤诊疗中的应用[J].中国医学计算机成像杂志, 2015, 21(05): 413-418.

[43] 熊志勇, 王旋, 张志平, 等. Angiopep-2修饰纳米颗粒穿越血脑脊液屏障的能力[J].华中科技大学学报：医学版, 2014, 43(03): 304-306+310.

[44] Mathew W Smith, Ghaith Al-Jayyoussi, Mark Gumbleton. Peptide sequences mediating tropism to intact blood-brain barrier: an in vivobiodistribution study using phage display[J]. Peptides, 2012, 38(1): 172−180.

[45] Nicole Ullrich, Harald Sontheimer. Human astrocytoma cells express a unique chloride current[J]. Neuroreport, 1996, 7(5):1020-1024．

[46] Nicole J Ullrich, Harald Sontheimer. Biophysical and pharmacological characterization of chloride currents in human astrocyloma cells[J].Am J Physiol, 1996, 270(5pt1):C1511-C1521.

[47] Jessy Deshane, Craig C Garner, Harald Sontheimer. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2[J].Biol Chem, 2003, 278(6):4135-4144．

[48] Pieter J Gaillard, Arjen Brink, Albertus G de Boer. Diphtheria toxin receptor-targeted brain drug delivery[J]. Int Cong Series, 2005, 1277(1):185-198.

[49] 刘洋, 蒋晨. 纳米药物递释系统的脑靶向研究进展[J]. 药学学报，2013, 48(10):1532-1543.

[50] Mu Chao-feng, Nimita Dave, Hu Jing, et al. Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro[J]. J Microencapsul, 2013, doi.org/10.3109/02652048.2013.778907.

[51] Sonu Bhaskar, Furong Tian, Tobias Stoeger, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging[J].Part Fibre Toxicol, 2010, 7:3.

[52] Azam Bolhassani. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer[J]. Biochim Biophys Acta, 2011, 1816(2): 232–246.

[53] Liu Li-hong, Guo Kun, Lu Jia, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG–TAT for drug delivery across the blood–brain barrier[J]. Biomaterials, 2008, 29(10):1509–1517.

[54] Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells [J]. Proc Natl Acad Sci USA, 1994, 91(2): 664−668.

[55] Melissa J Simon, Woo Hyeun Kang, Gao Shan, et al. Increased delivery of TAT across an endothelial monolayer following ischemic injury [J]. Neurosci Lett, 2010, 486(1): 1−4.

[56] Filipa L Cardoso, Dora Brites, Maria A Brito. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches[J]. Brain Res Rev, 2010, 64(2):328–363.

[57] David J Begley, Milton W Brightman. Structural and functional aspects of the blood-brain barrier, Progress in Drug Research, Fortschritte Der Arzneimittelforschung[J]. Progres Des Recherches Pharmaceutiques, 2003, 61: 39–78.

[58] Xie Fu-lan, Yao Nian, Qin Yao, et al. Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting[J]. Int J Nanomedicine, 2012, 7:163–175.

[59] Luis J Cruz, Paul J Tacken, Remco Fokkink, et al. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells[J]. Biomaterials, 2011, 32(28):6791–6803.

[60] 董秀秀, 杨春荣, 平洋, 等. 纳米载药系统脑靶向策略研究进展[J]. 广东化工, 2017, 44(07): 142-143.

[61] 韩立杰, 郭炜, 刘伟, 等. 透明质酸修饰载紫杉醇靶向脂质体抑制脑肿瘤干细胞的初步评价[J]. 中国医院药学杂志, 2015, 35(09): 773-776.

[62] 何媛, 张雅溶, 李秋霞, 等. 透明质酸修饰姜黄素壳聚糖纳米粒的制备及初步细胞毒性考察[J]. 中国医药工业杂志, 2015, 46(02): 162-167.

[63] 赵子明, 戚大石, 韩瑾, 等. 乳铁蛋白修饰的壳聚糖磁性纳米粒的制备、表征及海马神经细胞摄取[J]. 中南药学, 2014, 12(12): 1175-1178.

[64] Sudheesh Pilakka-Kanthikeel, Venkata Subba Rao Atluri, Vidya Sagar, et al. Targeted brain derived neurotrophic factors（BDNF）delivery across the bloodbrain barrier for neuro-protection using magnetic nano carriers：an in-vitro study[J]. PLoS One, 2013, 8(4):e62241.

[65] Lu Wei. Adsorptive-mediated brain delivery systems [J]. Curr Pharm Biotechnol, 2012, 13: 2340−2348.

[66] Shailendra Joshi, Rajinder P Singh-Moon, Jason A Ellis, et al. Cerebral hypoperfusion-assisted intraarterial deposition of liposomes in normal and glioma-bearing rats[J]. Neurosurgery, 2015, 76(1):92–100.

[67] Shailendra Joshi, Rajinder Singh-Moon, Mei Wang, et al. Cationic surface charge enhances early regional deposition of liposomes after intracarotid injection[J]. J Neuro-Oncol, 2014, 120(3):489–497.

[68] Shailendra Joshi, Rajinder P Singh-Moon, Mei Wang, et al. Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue[J]. J Neuro-Oncol, 2014, 118(1):73–82.

[69] 马宝花, 杨海, 刘雪丽, 等. 壳聚糖修饰的托氟啶固体脂质纳米粒的制备[J]. 中国药师, 2015, 18(12):2050-2053.

[70] 马宝花. 壳聚糖修饰TFu固体脂质纳米粒的初步研究[D].济南：山东大学, 2009.

[71] 黄雷鸣, 赵锦花, 王国成, 等. 聚合物辅料对P-糖蛋白抑制机制的研究进展[J].药学学报, 2010, 45(10): 1224-1231.

[72] 莫然, 肖衍宇, 平其能. 药物制剂技术在抑制P-糖蛋白外排作用中的应用研究近况[J].药学进展, 2009, 33(10): 446-451.

[73] Rupa D Dabholkar, Rishikesh M Sawant, Dimitriy A Mongayt, et al. Polyethylene glycol-phosphatidylethanolamine conjugate (PEGPE)- based mixed micelles: Some properties, loading with paclitaxel, and modulation of P- glycoprotein - mediated efflux[J]. Int J Pharm, 2006, 315(1/2):148-157.

[74] Elena V Batrakova, Li Shu, Sergey V Vinogradov, et al. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization [J]. J Pharmacol Exp Ther, 2001, 299(2): 483−493.

[75] Sonu Bhaskar, Furong Tian, Tobias Stoeger, et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood–brain barrier: perspectives on tracking and neuroimaging[J].Part Fibre Toxicol, 2010, 7:3.

[76] 杨媛, 娄琨, 梅兴国, 等. 受体介导的脑靶向药物递送系统研究进展[J]. 中国药学杂志, 2009, 44(23): 1761-1764.

[77] Z.L. Chen, M. Huang, X.R. Wang, et al.Transferrin-modified liposome promotes alpha-mangostin to penetrate the bloodbrain barrier[J]. Nanomedicine 12 (2016) 421–430.与26重复

[78] Lucienne Juillerat-Jeanneret. The targeted delivery of cancer drugs across the blood–brain barrier:chemical modifications of drugs or drug-nanoparticles?[J]. Drug Discov Today, 2008, 13(23–24):1099–1106.

[79] Ishii T, Asai T, Oyama D, et al. Treatment of cerebral ischemia-reperfusion injury with PEGylated liposomes encapsulating FK506 [J].FASEB J, 2012, 27(4):1362-1370.

[80] Gaillard PJ, Appeldoorn CC, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation[J].J Control Release,2012,164:364-369.与38重复

[81] Michele Garaglia, Livio Luongo, Giuseppina Salzano, et al. Stealth liposomes encapsulating zoledronic Acid: a new opportunity to treat neuropathic pain [J].Mol Pharm, 2013,10(3):1111-1118.